Abbott India Limited
NSE: ABBOTINDIAMarket Closed • NSE
Day range
52 week range
Abbott India Limited closed at INR26170.00 (+0.38%) on volume 0.49x its 20-day average, trading 14.63% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +8.5% QoQ
2026-07-24
DIVIDEND Announced
Dividend - Rs 525 Per Share & Special Dividend Rs 131 Per Share
2025-07-25
DIVIDEND Announced
Dividend - Rs 475 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Established operational history in the sector
Active institutional participation
Risks
Elevated Leverage Burden: Debt-to-Equity stands at 3.60x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Top reported holders
Largest named holdings disclosed for June 2026
Abbott Capital India Limited
PromoterAbbott Healthcare Products Limited
PromoterBritish Colloids Limited
PromoterSbi Nifty Midcap 150 Momentum 50 Etf
DIICanara Robeco Mutual Fund
DIINippon Life India Trustee Ltd
DIIComplete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 24 Jul 2026 | Dividend | ₹525.00 / share | — | 24 Jul 2026 |
| 25 Jul 2025 | Dividend | ₹475.00 / share | — | 25 Jul 2025 |
| 19 Jul 2024 | Dividend | ₹410.00 / share | — | 19 Jul 2024 |
| 21 Jul 2023 | Dividend | ₹180.00 / share | — | 21 Jul 2023 |
| — | Dividend | ₹145.00 / share | — | 02 Aug 2022 |
| — | Dividend | ₹120.00 / share | — | 19 Jul 2021 |
| — | Dividend | ₹107.00 / share | — | 28 Aug 2020 |
| — | Dividend | ₹50.00 / share | — | 13 Aug 2019 |
| — | Dividend | ₹50.00 / share | — | 10 Jul 2018 |
| — | Dividend | ₹40.00 / share | — | 10 Jul 2017 |
| — | Dividend | ₹35.00 / share | — | 08 Jul 2016 |
| — | Dividend | ₹31.00 / share | — | 22 Jul 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Abbott India Ltd is one of the leading multinational pharmaceutical companies in India and sells its products through independent distributors primarily within India.[1] It was established in 1944.[2]
IndiaHealthcare
Is Abbott India Limited Shariah compliant?
Abbott India Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (360.2%) exceeds AAOIFI threshold (≤ 33%).
What is Abbott India Limited's current valuation relative to peers?
Abbott India Limited trades at a P/E of 34.4x compared to the sector median of 37x, and a Price-to-Book of 11.6x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 3.60x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 1.6% while net profit growth averaged 1.9%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.